Starling Oncology, Inc. Announces Third Quarter 2026 Financial Results Release Date
Starling Oncology, Inc. (NASDAQ: STLN) has scheduled the release of its third quarter 2026 financial results for November 5, 2026.
Stocks · News reference
Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Starling Oncology shares are trading higher after the company reported a year-over-year decrease in Q2 loss per share and increase in sales results.
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in